[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Visit from Guillaume Pépy, President of Initiative France

Hemerion welcomes Guillaume Pépy, Chairman of Initiative France

On Tuesday September 26th, Hemerion welcomed Guillaume Pépy, President of Initiative France, at the head of a delegation made up of representatives of the Initiative France network and its partners, specialists in the creation of innovative companies.
This was an opportunity to highlight the clinical progress made by our team in the treatment of glioblastoma and to demonstrate the operation of the latest version of our Heliance® illumination platform.

Founded in 2020, Hemerion received early funding from Hodéfi, a major player in the creation of innovative companies in the French Hauts-de-France region and a member of the national Initiative France network, which brings together over 200 associations in France dedicated to business creation and takeovers. Each year, Initiative France supports the creation of more than 20,000 businesses throughout France.

On the occasion of Hodefi’s 40th anniversary, Hemerion welcomed a delegation led by Guillaume Pepy, Chairman of Initiative France and former Chairman of the SNCF (French national railways).

The delegation included representatives from Initiative France, Hodéfi and BNP Paribas, as well as several journalists (Les Echos, La Voix du Nord, J’aime les Start-Ups, IT for Business, la Gazette du Nord).

Discussions with the delegation focused on Hemerion’s rapid progress in clinical development, with the recent FDA approval for a clinical trial in the US, and its financing plan. The delegation was able to participate in a full-scale demonstration of the use of Hemerion’s Heliance® illumination platform designed to improve the treatment of glioblastoma.